Are calcium antagonists effective in preventing complications of hypertension and progression of renal disease?

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 5, 2000, Pages 489-495

  Laing, C ^a   Unwin, R J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; BENZOTHIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FOSINOPRIL; ISRADIPINE; LACIDIPINE; LISINOPRIL; M PROTEIN; NIFEDIPINE; NISOLDIPINE; PHENYLALKYLAMINE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VASODILATOR AGENT; VERAPAMIL;

ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CELL PROTECTION; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; KIDNEY DISEASE; MEDICAL SOCIETY; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; WORLD HEALTH ORGANIZATION;

CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; RISK FACTORS;

EID: 0033849756     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200009000-00005     Document Type: Review

References (52)

1. Prevalence of hypertension in patients on peritoneal dialysis: Results of an Italian multicentre study
2. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients
3. Prevalence of hypertension in a hemodialysis population
4. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989
5. Risk factors of renal failure progression two years prior to dialysis
6. Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisited
7. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
8. Comparison of two strategies for intensifying antihypertensive treatment: Low-dose combination (enalapril+ felodipine ER) versus increased dose of monotherapy (enalapril)
9. Optimisation of antihypertensive treatment by crossover rotation of four major classes
10. Calcium-antagonist drugs
11. The risk of myocardial infarction associated with antihypertensive drug therapies
12. Long-term survival and use of antihypertensive medications in older persons
13. The calcium antagonist controversy: A post-humous commentary
14. Safety of nifedipine in angina pectoris: A meta-analysis
15. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina
16. Cardiovascular and renal risks of calcium-channel blockers news from the HOT study
17. Blood pressure control in type 2 diabetes-what does the United Kingdom Prospective Diabetes Study (UKPDS) tell us?
18. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension
19. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators
20. Systolic hypertension in Europe (Syst-Eur) trial phase 2: Objectives, protocol, and initial progress. Systolic Hypertension in Europe Investigators
21. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
22. Antihypertensive therapy in type 2 diabetes: Implications of the appropriate blood pressure control in diabetes (ABCD) trial
23. Comorbidity of hypertension and diabetes: The fosinopril versus amlodipine cardiovascular events trial (FACET)
24. The management of hypertensive disease in black patients
25. Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril
26. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): An Internet-based randomized trial in coronary artery disease patients with hypertension
27. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease
28. Antihypertensive effect of trandolapril and verapamil in rats with induced hypertension
29. Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats
30. Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine
31. Lacidipine protects against cyclosporine-induced nephrotoxicity in rats
32. Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis
33. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: A randomised trial
34. Renal effects of amlodipine in normotensive renal transplant recipients
35. Use of calcium-channel blockers in pediatric renal transplant recipients
36. Renal effects of efonidipine hydrochloride, a new calcium antagonist, in spontaneously hypertensive rats with glomerular injury
37. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats
38. Therapeutic effects of a calcium antagonist, lacidipine, on stroke-prone spontaneously hypertensive rats with cerebrovascular lesions
39. Cardiovascular risk, renal hypertensive damage, and effects of amlodipine treatment in transgenic TGR(mREN2)27 rats
40. Treatment with a Ca(2+) channel blocker, barnidipine, reduces platelet-derived growth factor B-chain mRNA in glomeruli of spontaneously hypertensive rats
41. Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats
42. Effect of calcium channel blockers, nifedipine and benidipine, on death of cultured mouse mesangial cells
43. Antiproteinuric effect of calcium antagonists on puromycin-induced experimental nephrosis
44. Effects of amlodipine on tubulointerstitial lesions in normotensive hyperoxaluric rats
45. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function
46. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies
47. Effect of the calcium channel blocker nitrendipine in normotensive and spontaneously hypertensive, diabetic rats on kidney morphology and urinary albumin excretion
48. Renal afferent and efferent arteriolar dilation by nilvadipine: Studies in the isolated perfused hydronephrotic kidney
49. Class differences in the effects of calcium channel blockers in the rat remnant kidney model
50. Calcium channel blockers the effect on renal changes in clinical and experimental diabetes: An overview
51. The effect of long, slow haemodialysis on patient survival